Clinical Trial Update: Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating oral vernakalant to prevent recurrence of atrial fibrillation after conversion has completed. The trial was sponsored by Advanz Pharm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Vernakalant (vernakalant)

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED